Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective observational study of Prolia (denosumab) in Chinese postmenopausal women with osteoporosis
CTR20230462Phase 4Active
- Sponsor
- Amgen
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of denosumab in osteoporosis, sponsored by Amgen. Primary endpoint: Incidence of adverse events, serious adverse events, and adverse drug reactions. Started May 2023; status: active.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on CTR20230462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230462.